Bacopa Monnieri
Bacopa monnieri, also called brahmi, is an herb used in traditional Ayurvedic practice as a nerve tonic and memory aid. Its main active compounds are called bacosides. In placebo-controlled trials in healthy adults, standardized extracts taken at 300 to 450 mg a day for about 12 weeks improved scores on several memory tests, especially delayed recall and retention of newly learned word lists. A meta-analysis of nine trials found faster attention speed, measured as quicker Trail Making and choice reaction times. Two trials also reported lower anxiety scores, while a third found no change. In these trials, benefits were measured after about 12 weeks of daily use. Not every trial agrees: a 450 mg trial in 72 adults and a 300 mg trial in 101 adults with memory complaints found no cognitive benefit over placebo. The most common side effects are digestive: more frequent stools, abdominal cramps and nausea.
Benefits
Memory consolidation and recall of new information
In placebo-controlled trials lasting about 12 weeks, standardized bacopa extracts improved retention of newly learned word lists and delayed recall in healthy adults, including people over 55 and over 65. A systematic review of six such trials found improvement on 9 of 17 memory free-recall tests, with little evidence for other cognitive areas. Benefits were measured after about 12 weeks of daily use.
Faster information processing and attention speed
A meta-analysis of nine placebo-controlled trials lasting at least 12 weeks found shorter Trail Making B times and faster choice reaction time with bacopa, pointing to quicker attention. One trial also found faster visual information processing and a better learning rate, and another found better spatial working memory accuracy. A third trial found learning rate unchanged, so results vary by test.
Lower anxiety scores in healthy adults
In a 12-week trial in healthy adults, bacopa lowered state anxiety compared with placebo. In adults aged 65 and over, combined state and trait anxiety scores fell with bacopa while rising with placebo. A third 12-week trial in adults aged 40 to 65 found no change in anxiety. All three trials were small.
Memory support in healthy older adults
Two 12-week placebo-controlled trials in healthy people over 55 and over 65 found better verbal learning and delayed word recall with 300 mg a day of standardized extract. Lab and animal studies suggest antioxidant and cholinergic actions, but these 12-week trials did not test long-term effects on brain aging.
Attention and behavior in children and teens
A systematic review of five studies in children and adolescents reported improvements in language, several memory measures, and attention and hyperactivity ratings, with small to medium effect sizes (average d of 0.42). About 2 percent of participants reported mild side effects. A later trial in 93 boys aged 6 to 14, funded by the extract seller, found no difference from placebo on its main behavior ratings. Any use in a child should be discussed with a pediatrician.
Digestive side effects to expect
In a 12-week trial in adults over 55, bacopa caused more digestive side effects than placebo: more frequent stools, abdominal cramps and nausea. In a trial in adults over 65, adverse events were few and similar in number to placebo (9 versus 10), mostly stomach upset. The trials did not test whether taking bacopa with food reduces these effects.
Trials used standardized extracts
The positive trials used standardized bacopa extracts such as KeenMind and BacoMind at 300 mg a day, and a systematic review noted three different extracts tested at 300 to 450 mg a day. Results from these extracts may not apply to unstandardized whole-herb powders, which these trials did not test. Label bacoside percentages depend on the test (one extract read 45 percent by UV and 11 percent by HPLC), so brands cannot be compared by percentage.
Mechanism of action
Cholinergic activity
In lab and animal studies, bacopa compounds inhibited acetylcholinesterase, the enzyme that breaks down the memory-related messenger acetylcholine, and may activate choline acetyltransferase, the enzyme that makes it. These effects have not been measured directly in people.
Blood flow and neurotransmitter effects
A review of preclinical research describes increased blood flow to the brain, changes in acetylcholine, serotonin and dopamine signaling, and reduced beta-amyloid in animal models.
Antioxidant activity in nerve tissue
The same review describes antioxidant protection of nerve cells through redox effects and induction of antioxidant enzymes in animal and lab studies, which may help limit oxidative damage.
Clinical trials
Meta-analysis of randomized, placebo-controlled trials of standardized Bacopa monnieri extracts dosed for at least 12 weeks without other medication, searched through June 2013, with risk of bias assessed. (Kongkeaw et al. 2014, J Ethnopharmacol)
Nine trials with 518 participants; 437 eligible participants were pooled in the meta-analysis.
Bacopa shortened Trail Making B time and choice reaction time compared with placebo, pointing to faster attention. No other pooled outcomes were reported as significant. The authors concluded Bacopa has potential to improve cognition, but that only a large head-to-head trial against an existing medication would give definitive efficacy data.
Randomized, double-blind, placebo-controlled trial of BacoMind (300 mg/day) vs placebo for 12 weeks. Outcomes: Rey Auditory Verbal Learning Test (AVLT), Rey-Osterrieth Complex Figure Test, Trail Making Test, and a memory complaint questionnaire. (Morgan et al. 2010, J Altern Complement Med)
Healthy adults over age 55; 98 started and 81 completed.
Bacopa significantly improved verbal learning, memory acquisition and delayed recall on the AVLT vs placebo. Complex Figure, memory complaint and Trail Making scores improved but did not differ significantly from placebo. Bacopa caused more digestive side effects: increased stool frequency, abdominal cramps and nausea.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Bacopa Monnieri
How much bacopa should I take?
The controlled trials used 300 to 450 mg per day of a standardized extract, most often 300 mg once daily, for 12 weeks. Follow the label of a standardized product and check with your doctor if you take other medications.
How long does bacopa take to work?
Bacopa is slow to build. In trials, memory and processing-speed benefits were measured after about 12 weeks of daily use, and one trial that tested at 5 and 12 weeks saw the largest effects at 12 weeks. Three small single-dose studies gave mixed results (one found no change; two found gains on some tasks in the hours after 320 mg), so bacopa is studied as a daily supplement.
Should I take bacopa with food?
Digestive upset is the most common side effect in trials, so taking it with a meal is a reasonable way to try to reduce stomach discomfort. The trials did not compare taking it with or without food.
Does bacopa have side effects?
The most common are digestive: more frequent stools, abdominal cramps and nausea. A mouse study found bacopa raised the thyroid hormone T4, so people on thyroid medication should check with their doctor, as should anyone taking sedatives or acetylcholinesterase inhibitor drugs.
What is Bacopa Monnieri?
Bacopa monnieri, also called brahmi, is an herb used in traditional Ayurvedic practice as a nerve tonic and memory aid. Its main active compounds are called bacosides.
What is Bacopa Monnieri used for?
Bacopa Monnieri is researched primarily for Cognitive and Stress & Anxiety. In placebo-controlled trials lasting about 12 weeks, standardized bacopa extracts improved retention of newly learned word lists and delayed recall in healthy adults, including people over 55 and over 65.
Does Bacopa Monnieri interact with any medications?
Possible interactions include: Acetylcholinesterase inhibitors (donepezil, rivastigmine): bacopa inhibits the same enzyme in lab studies, so additive cholinergic effects are theoretically possible; ask your doctor Thyroid medications: a bacopa extract raised T4 thyroid hormone in male mice; human effects are u… If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Bacopa Monnieri?
NutraSmarts rates the evidence for Bacopa Monnieri as Moderate (3 out of 5). It is backed by 2 study summaries and 19 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(19 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). 2001;156(4):481-4. doi: 10.1007/s002130100815.PubMedUsed to support: Double-blind placebo-controlled trial in healthy adults: Keenmind (300 mg/day) significantly improved speed of visual information processing, learning rate, memory consolidation on the AVLT, and state anxiety vs placebo, with maximal effects after 12 weeks (tested at 5 and 12 weeks). An erratum on a dosage error in the article text was published in 2015.
- Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279-81. doi: 10.1016/S0893-133X(01)00419-5.PubMedUsed to support: Double-blind RCT in 76 adults aged 40 to 65: 3 months of Bacopa improved retention of new information vs placebo, suggesting slower forgetting. Learning rate, attention, verbal and visual short-term memory, everyday memory questionnaires and anxiety were unaffected.
- Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707-13. doi: 10.1089/acm.2008.0018.PubMedUsed to support: 12-week RCT in 54 adults aged 65 and over without dementia (48 completed): Bacopa improved AVLT delayed word recall and Stroop performance, and CESD-10 depression scores, combined state plus trait anxiety and heart rate fell vs placebo. No effects on divided attention, the WAIS digit task, mood or blood pressure; adverse events were few (9 vs 10), mainly stomach upset.
- Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008;22(12):1629-34. doi: 10.1002/ptr.2537.PubMedUsed to support: 90-day randomized placebo-controlled trial (107 enrolled, 62 completed) using the Cognitive Drug Research battery: KeenMind (2 x 150 mg/day) significantly improved the Working Memory factor (spatial working memory accuracy) and reduced false positives on the rapid visual information processing task vs placebo.
- Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med. 2010;16(7):753-9. doi: 10.1089/acm.2009.0342.PubMedUsed to support: 12-week double-blind RCT in healthy adults over 55 (98 started, 81 completed): BacoMind 300 mg/day improved AVLT verbal learning, memory acquisition, delayed recall and retroactive interference vs placebo; Complex Figure, memory complaint and Trail Making differences were not significant. Bacopa caused more digestive side effects (increased stool frequency, abdominal cramps, nausea).
- The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18(7):647-52. doi: 10.1089/acm.2011.0367.PubMedUsed to support: Systematic review of 6 randomized controlled trials, all conducted over 12 weeks at 300 to 450 mg/day: Bacopa improved performance on 9 of 17 tests of memory free recall, with little evidence of enhancement in other cognitive domains. The authors note the nootropic research on Bacopa is still at an early stage.
- Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313-26. doi: 10.1089/rej.2013.1431.PubMedUsed to support: Narrative review of behavioral and molecular research on Bacopa monnieri: preclinical evidence for antioxidant neuroprotection, acetylcholinesterase inhibition and/or choline acetyltransferase activation, beta-amyloid reduction, increased cerebral blood flow and neurotransmitter modulation, with low toxicity in model organisms and humans; long-term human toxicity studies had not been done.
- A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations. Complement Ther Med. 2016;29:56-62. doi: 10.1016/j.ctim.2016.09.002.PubMedUsed to support: Systematic review of five studies of Bacopa in children and adolescents (no restriction on study design): significant improvements in the language behaviour cognitive domain, several memory sub-domains, and hyperactivity and attention-deficit domains, with small-to-medium effect sizes (mean Cohen d = 0.42). Mild side effects were reported by 2.3 percent of participants. The authors call for replicated study designs and stringent statistical analysis to validate these outcomes.
- Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528-35. doi: 10.1016/j.jep.2013.11.008.PubMedUsed to support: Meta-analysis of randomized placebo-controlled trials of standardized Bacopa extracts dosed for at least 12 weeks without co-medication: nine studies with 518 subjects met the criteria and 437 eligible subjects were pooled. Bacopa shortened Trail B time and choice reaction time, pointing to faster attention; no other pooled outcomes were reported as significant. The authors say only a large head-to-head trial against an existing medication would give definitive efficacy data.
- Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice. J Ethnopharmacol. 2002;81(2):281-5. doi: 10.1016/s0378-8741(02)00048-x.PubMedUsed to support: Animal study: a Bacopa monnieri extract (200 mg/kg) raised serum T4 thyroid hormone by about 41 percent in male mice. No human data; cited as the basis for the thyroid medication caution.
- Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopa monniera) in healthy adults. Psychopharmacology (Berl). 2013;227(2):299-306. doi: 10.1007/s00213-013-2978-z.PubMedUsed to support: Randomized, placebo-controlled trial in 72 healthy adults aged 35 to 60 given 450 mg a day for 12 weeks: no significant differences from placebo on any cognitive measure, with only a trend toward lower state anxiety.
- The Effects of a Bacopa monnieri Extract (Bacumen(®)) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Drug Investig. 2025;45(12):967-982. doi: 10.1007/s40261-025-01492-1.PubMedUsed to support: Randomized trial of the branded extract Bacumen, 300 mg a day for 12 weeks in 101 adults aged 40 to 70 with self-reported memory and attention problems: its primary cognitive outcomes were not met; self-rated stress reactivity improved as a secondary measure.
- Effects of Bacopa monnieri (CDRI 08®) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years: A randomized, double-blind, placebo-controlled trial. Phytother Res. 2022;36(2):996-1012. doi: 10.1002/ptr.7372.PubMedUsed to support: Randomized trial of the CDRI 08 extract for 14 weeks in boys aged 6 to 14 with inattention and hyperactivity (93 analyzed): no significant difference from placebo on the main parent-rated behavior scale; some secondary measures favored bacopa. Funded by a grant from Soho Flordis International.
- An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother Res. 2013;27(9):1407-13. doi: 10.1002/ptr.4864.PubMedUsed to support: Single-dose crossover study in 24 healthy adults: 320 mg of the CDRI 08 extract improved performance on some repetitions of a demanding cognitive test battery; stress and fatigue ratings did not change.
- An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res. 2014;28(4):551-9. doi: 10.1002/ptr.5029.PubMedUsed to support: Single-dose crossover study in 17 healthy adults: the CDRI 08 extract improved some multitasking scores 1 and 2 hours after dosing, with some positive mood effects and lower cortisol; the authors call for replication.
- The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Hum Psychopharmacol. 2001;16(4):345-351. doi: 10.1002/hup.306.PubMedUsed to support: Single 300 mg dose versus placebo in healthy adults, tested 2 hours later: no significant changes in cognitive function.
- Validation of Quantitative HPLC Method for Bacosides in KeenMind. Evid Based Complement Alternat Med. 2015;2015:696172. doi: 10.1155/2015/696172.PubMedUsed to support: Lab method paper: a British Pharmacopoeia HPLC method gives far lower bacoside values for the KeenMind (CDRI 08) extract than broad UV methods, so bacoside percentages measured by different tests are not comparable. One author is from Soho Flordis.
- Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules. 2014;19(2):2588-601. doi: 10.3390/molecules19022588.PubMedUsed to support: Lab study: a standardized bacopa extract inhibited the drug-clearing enzymes CYP2C19, CYP2C9, CYP1A2 and CYP3A4, while isolated bacosides had little effect. Not tested in people.
- Evaluation of memory enhancing clinically available standardized extract of Bacopa monniera on P-glycoprotein and cytochrome P450 3A in Sprague-Dawley rats. PLoS One. 2013;8(8):e72517. doi: 10.1371/journal.pone.0072517.PubMedUsed to support: Rat study: a week of a standardized bacopa extract lowered liver CYP3A activity and raised blood levels of carbamazepine about fourfold. Not tested in people.